Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Bristol Myers Squibb - GI Cancers – I-O Regimens in the First Line and Beyond

The Expanding Role of I-O Therapies for Esophageal Cancer: Where Are We Today?

Date

21 Nov 2021

Session

Bristol Myers Squibb - GI Cancers – I-O Regimens in the First Line and Beyond

Topics

Immunotherapy

Tumour Site

Gastrointestinal Cancers

Presenters

Hisato Kawakami

Authors

H. Kawakami

Author affiliations

  • Medical Oncology, Kindai University - Faculty of Medicine, 589-8511 - Osaka/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.